Assentus Biogenics Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 15-12-2024
- Paid Up Capital ₹ 5.95 M
as on 15-12-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.01 Cr
as on 15-12-2024
- Revenue -47.22%
(FY 2020)
- Profit -19366.35%
(FY 2020)
- Ebitda -40.78%
(FY 2020)
- Net Worth -97.80%
(FY 2020)
- Total Assets -15.55%
(FY 2020)
About Assentus Biogenics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 5.95 M.
The company currently has active open charges totaling ₹1.01 Cr.
Soumyen Basak, Debasis Chakrabarti, and Kabita Basak serve as directors at the Company.
- CIN/LLPIN
U24100WB2013PTC195114
- Company No.
195114
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jun 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Assentus Biogenics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Debasis Chakrabarti  | Director | 30-Sep-2023 | Current |
| Soumyen Basak | Director | 01-Apr-2015 | Current |
| Kabita Basak | Additional Director | 27-Feb-2021 | Current |
Financial Performance of Assentus Biogenics.
Assentus Biogenics Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 47.22% decrease. The company also saw a substantial fall in profitability, with a 19366.35% decrease in profit. The company's net worth observed a substantial decline by a decrease of 97.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Assentus Biogenics?
In 2017, Assentus Biogenics had a promoter holding of 21.00% and a public holding of 79.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Aug 2024 | ₹5.00 M | Open |
Others Creation Date: 22 Oct 2020 | ₹0.80 M | Open |
Others Creation Date: 09 Sep 2020 | ₹0.28 M | Open |
How Many Employees Work at Assentus Biogenics?
Assentus Biogenics has a workforce of 15 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Assentus Biogenics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Assentus Biogenics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
